An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir in Adults with Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, with Severe Kidney Impairment or End-Stage Kidney Disease (RUBY-II) Estudio abierto para evaluar eficacia y seguridad de Ombitasvir/Paritaprevir/Ritonavir con o sin Dasabuvir en adultos con infección crónica por el virus de la Hepatitis C (VHC) de los genotipos 1a o 4 con insuficiencia renal grave o nefropatía terminal (RUBY-II) The primary objective of this study is to assess the safety and efficacy (the percentage of subjects achieving a 12-week sustained virologic response, SVR12 [HCV ribonucleic acid (RNA) < lower limit o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Étude M15-819 : étude de phase 1 évaluant l’efficacité et la sécurité de l'ABBV-428 seul ou en association avec du nivolumab chez des patients ayant des tumeurs solides de stade avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cancers humains. La neurotensine...

• Pays France
• Organes Tumeurs solides
• Spécialités Immunothérapie - Vaccinothérapie

An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy with Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection HCV RNA early viral load decline in the plasma following combination of ombitasvir/ABT-450/r and dasabuvir administered with low dose, full dose, or no RBV in treatment-naive HCV genotype GT 1a-infect...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to Compare ABT-494 to Abatacept in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-CHOICE) 1. To compare the safety and efficacy of ABT-494 versus abatacept intravenous (IV) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDM...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE) To compare a treat-to-target (T2T) intense treatment approach with a routine treatment approach (Standard of Care [SOC]) in reducing disease activity at week 32 in patients with axial spondyloarthriti...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB To evaluate the efficacy of GDC-0199 and rituximab (GDC-0199+R) compared with bendamustine and rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) as measured by ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate The primary objectives are to compare the efficacy of ABT-122 versus placebo in subjects on background methotrexate (MTX) as assessed by ACR20 at Week 12 and to assess the safety and tolerability of A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis To evaluate the Long-Term Safety and Efficacy of ABT-494

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma The primary objective of study is to assess if the addition of ABT-888 to temozolomide (TMZ) can prolong Progression Free Survival (PFS) compared to TMZ alone in subjects with metastatic melanoma (MM)...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Rapidity of response to adalimumab treatment in patients with Crohn´s Disease. Rapidez en la respuesta al tratamiento con Adalimumab en pacientes con Enfermedad de Crohn To evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease Evaluar la rapidez del inicio de la respuesta clínica al tratamiento con Ada...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune